Skip to main content
Caplight Logo









Amberstone Biosciences

Amberstone Biosciences

Private
Irvine, CaliforniaHealthcare & Life Scienceshttps://amberstonebio.com/web/

Last Round

Series A

Jan 3, 2022

Total Funding Raised

$12.23M

Company Overview

Amberstone Biosciences is a biotechnology company developing a novel class of targeted and conditionally active immunotherapeutics to treat solid tumor cancers.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Application

Keywords

immunotherapysolid tumor therapyimmuno-oncologydrug discovery platformTME-activated therapybispecific antibodiessmart biologicsconditional activationpH-sensitive antibodiesT-cell engagersantibody discoverysingle-cell discoveryoff-tumor toxicity reductionimmunocytokinesIND-enabling studiesmicrofluidicsAI in drug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Amberstone Biosciences Comparables

Compare Amberstone Biosciences with similar companies based on industry and business-model similarity.

Amberstone Biosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Bonum Therapeutics
89%
Tentarix Biotherapeutics
82%
Werewolf Therapeutics
77%

Amberstone Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJan 3, 2022
GrantAug 29, 2019

Key People

Founding team and executive leadership

George Wu

Founder & CEO

Founding Team

Yonglei Shang

SVP CTO, SVP, Head Of Discovery And Early Development, VP, Head Of Antibody Therapeutics

Executive Team

Amberstone Biosciences Investors

Notable investors and investment history

Amberstone Biosciences investors
InvestorRounds
Co-Win VenturesSeries A
Viva BioInnovatorSeries A
Sinovation VenturesSeries A
National Science FoundationGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 19, 2026

    Monthly visitors grew 461% MoM, from 285 to 1.6K.

  • Nov 7, 2025

    Monthly visitors grew 61% MoM, from 664 to 1.1K.

Amberstone Biosciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Amberstone Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Amberstone Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersIrvine, California
Employee Range15
Year Founded2018
Last FundingJan 3, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?